Why the study?
Is there an intrasubject correlation between the pharmacokinetics of warfarin enantiomers and racemic warfarin in healthy men?
Is there an intrasubject correlation between the pharmacokinetics of warfarin enantiomers and racemic warfarin in healthy men?
The maintenance dose of racemic warfarin is a useful predictor for the required dose of S(-)-warfarin to achieve comparable anticoagulation, but not for R(+)-warfarin.
Answers are grounded in this paper and cite their sources.
Racemic dose may estimate S-warfarin needs in healthy subjects; leaves open clinical translation and patient outcomes.
The total body clearance of single doses of R(+)-, S(-)-, and racemic warfarin and the plasma concentration-anticoagulant effect curves for these drugs were determined in 10 healthy men, 21 to 51 yr old. This information was used to calculate the steady-state dose required to decrease prothrombin complex activity to about 30% of normal. This dose (mean +/- SD in mg/70 kg/day) is 17.8 +/- 9.3 for R(+)-warfarin, 6.63 +/- 2.19 for S(-)-warfarin, and 9.4 +/- 1.7 for racemic warfarin. There is a correlation between the maintenance doses of racemic and S(-)-warfarin (r = 0.89, p less than 0.01) but not between those of racemic and R(+)-warfarin (r = 0.30, NS). According to these calculations, the maintenance dose of racemic warfarin required by an individual patient may be a useful predictor of maintenance dose of S(-)-warfarin which will produce a comparable degree of anticoagulation. No such predictability is evident with respect to R(+)-warfarin. The slopes of the log plasma concentration-anticoagulant effect curves for R(+)-and S(-)-warfarin differ significantly. Therefore, the potency ratio of these enantiomers is dose-and concentration-dependent.
No takes yet. Share an insight, caveat, or question.
Wingard et al. (1978) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: